Christopher Kiritsy Biography and Net Worth



Mr. Kiritsy is founder and managing member of Precision Kapital, LLC, a private investment and advisory firm. Prior to forming Precision Kapital, Mr. Kiritsy teamed up with the late pharmaceutical legend, Michael Jaharis, to co-found Arisaph Pharmaceuticals and served as Arisaph’s President and Chief Executive Officer from 2005 through 2018. Prior to Arisaph, Mr. Kiritsy served as Executive Vice President, Corporate Development and Chief Financial Officer of Kos Pharmaceuticals, Inc., where he played a key operating role in building the company from start-up to highly profitable, publicly traded, commercial company, in which Kos internally developed and commercialized the blockbuster Niaspan® franchise. Mr. Kiritsy spearheaded more than 10 major corporate development transactions and raised approximately $500 million in public equity, including Kos’ initial public offering. Kos was acquired by Abbott Laboratories for $3.7 billion in 2016. Additionally, Mr. Kiritsy has broad corporate governance experience, previously serving as board member and various committee chairs of multiple public and private companies. Mr. Kiritsy also serves as an advisor to Red Sky Partners, LLC. Mr. Kiritsy is a seasoned entrepreneur, who possesses 30 years of industry experience, building emerging biopharmaceutical companies with expertise in R&D, business development and finance.

What is Christopher P. Kiritsy's net worth?

The estimated net worth of Christopher P. Kiritsy is at least $38.30 thousand as of September 2nd, 2026. Mr. Kiritsy owns 250 shares of Palvella Therapeutics stock worth more than $38,296 as of September 9th. This net worth evaluation does not reflect any other assets that Mr. Kiritsy may own. Learn More about Christopher P. Kiritsy's net worth.

How do I contact Christopher P. Kiritsy?

The corporate mailing address for Mr. Kiritsy and other Palvella Therapeutics executives is 225 Franklin Street 26th Floor, Boston MA, 02110. Palvella Therapeutics can also be reached via phone at 857-246-8998 and via email at [email protected]. Learn More on Christopher P. Kiritsy's contact information.

Has Christopher P. Kiritsy been buying or selling shares of Palvella Therapeutics?

Within the last three months, Christopher P. Kiritsy has sold $49,141.00 in shares of Palvella Therapeutics stock. Most recently, Christopher P. Kiritsy sold 313 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $157.00, for a transaction totalling $49,141.00. Following the completion of the sale, the director now directly owns 250 shares of the company's stock, valued at $39,250. Learn More on Christopher P. Kiritsy's trading history.

Who are Palvella Therapeutics' active insiders?

Palvella Therapeutics' insider roster includes Kathleen Goin (COO), Elaine Heron (Director), George Jenkins (Director), and Christopher Kiritsy (Director). Learn More on Palvella Therapeutics' active insiders.

Are insiders buying or selling shares of Palvella Therapeutics?

In the last twelve months, Palvella Therapeutics insiders bought shares 2 times. They purchased a total of 6,400 shares worth more than $800,000.00. In the last twelve months, insiders at the sold shares 7 times. They sold a total of 26,125 shares worth more than $2,893,881.52. The most recent insider tranaction occured on September, 2nd when Director Christopher P. Kiritsy sold 313 shares worth more than $49,141.00. Insiders at Palvella Therapeutics own 17.2% of the company. Learn More about insider trades at Palvella Therapeutics.

Information on this page was last updated on 9/2/2026.

Christopher P. Kiritsy Insider Trading History at Palvella Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/2/2026Sell313$157.00$49,141.00250View SEC Filing Icon  
See Full Table

Christopher P. Kiritsy Buying and Selling Activity at Palvella Therapeutics

This chart shows Christopher P. Kiritsy's buying and selling at Palvella Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Palvella Therapeutics Company Overview

Palvella Therapeutics logo
Palvella Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases. Palvella Therapeutics Inc., formerly known as Pieris Pharmaceuticals Inc., is based in WAYNE, Pa.
Read More

Today's Range

Now: $152.56
Low: $145.91
High: $155.00

50 Day Range

MA: $148.39
Low: $124.15
High: $157.77

2 Week Range

Now: $152.56
Low: $53.30
High: $161.38

Volume

90,055 shs

Average Volume

264,196 shs

Market Capitalization

$2.20 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A